Spin trap nitronyl hindered phenols

Abstract

The invention is the use of nitronyl substituted hindered phenols as antioxidants in therapeutic applications. In the preferred embodiment the compositions have the general formula: Wherein R1 is hydrogen, an alkyl or an aryl and R2 is an alkyl or an aryl; R3 is an alkyl; and R4 is an alkyl. Further, the invention relates to novel compositions useful as antioxidants. The novel compounds include: 2,6-di-tert-butyl-4-(N-tert-octyl)nitronyl phenol (DBONP); 2,6-dimethyl-4-(N-tert-octyl)nitronyl phenol (DMONP); N-tert-octyl-C-phenyl nitrone (OPN).

We claim: 
     
       1. A compound according to the formula: ##STR25## 
     
     
       2. A pharmaceutical composition comprising a pharmacologically effective amount of a compound as claimed in claim 1, and a pharmaceutically acceptable carrier. .Iadd.3. A pharmaceutical composition comprising a pharmacologically effective amount of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol and a pharmaceutical vehicle suitable for administration to a patient. .Iaddend..Iadd.4. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for oral administration to a patient. .Iaddend..Iadd.5. The pharmaceutical composition of claim 4 wherein the vehicle comprises a fat-soluble substance. .Iaddend..Iadd.6. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for intravenous 
     
     
        administration to a patient. .Iaddend..Iadd.7.  The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for subcutaneous administration to a patient. .Iaddend..Iadd.8. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for intraperitoneal administration to a patient. .Iaddend..Iadd.9. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for topical administration to a patient. .Iaddend..Iadd.10. The pharmaceutical composition of claim 3 wherein the pharmacologically effective amount is an amount providing a dosage of between about 25 to about 250 milligrams of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol per kilogram of patient body weight. .Iaddend..Iadd.11. A method for treating a medical condition associated with free radicals comprising administering to a patient suffering from said condition an effective, free radical-quenching dosage of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol. 
     
     
        .Iaddend..Iadd.12.  A method for preventing a medical condition associated with free radicals comprising administering to a patient susceptible to said condition an effective, free radical-quenching dosage of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol. .Iaddend..Iadd.13. The method of claim 11 or 12 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered systematically. .Iaddend..Iadd.14. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered orally. .Iaddend..Iadd.15. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered intravenously. .Iaddend..Iadd.16. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered topically. .Iaddend..Iadd.17. The method of claim 13 wherein said free radicals are the result of inflammation effects. .Iaddend..Iadd.18. The method of claim 13 wherein said free radicals are the result of septic shock. .Iaddend..Iadd.19. The method of claim 13 wherein said free radicals are the result of ischemia/reperfusion. 
     
     
        .Iaddend..Iadd.20.  The method of claim 13 wherein said free radicals are the result of liver edema septic shock. .Iaddend..Iadd.21. The method of claim 13 wherein said free radicals are the result of liver edema fatigue stress. .Iaddend.